BioScrip surges on M&A speculation following CVS Coram acquisition

BioScrip (BIOS +18.5%) shares surge following renewed M&A speculation on the back of this morning's CVS acquisition of Coram for $2.1B.

Market chatter is referencing Jefferies' opinion the BioScrip could realistically fetch $12-$14/share, an 83% premium from the current price.

The stock has been downtrodden as of late, with shares having fallen 66.5% into yesterday's close from June highs.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs